What is Alimera Sciences?
Alimera Sciences is dedicated to the development and commercialization of prescription ophthalmic pharmaceuticals, with a strategic focus on diseases affecting the retina. These conditions, often associated with aging populations, represent a significant unmet medical need, driving Alimera's commitment to innovation in this specialized area of medicine. The company's work aims to provide improved therapeutic options for millions of patients worldwide.
How much funding has Alimera Sciences raised?
Alimera Sciences has raised a total of $380.6M across 12 funding rounds:
Stock Offering
$72M
Share Placement
$40M
Share Placement
$37.5M
Debt
$35M
Stock Offering
$26.5M
Debt
$40M
Share Placement
$20M
Debt
$45M
Debt
$1M
Stock Issuance/Offering (2010): $72.1M, investors not publicly disclosed
Share Placement (2012): $40M backed by Sofinnova Ventures and Palo Alto Investors
Share Placement (2014): $37.5M, investors not publicly disclosed
Debt (2014): $35M led by Hercules Technology Growth Capital, Inc
Stock Issuance/Offering (2016): $26.5M, investors not publicly disclosed
Debt (2018): $40M featuring Solar Capital Ltd.
Share Placement (2019): $20M backed by Lincoln Park Capital
Debt (2020): $45M with participation from Solar Capital Partners
Debt (2020): $1M led by PPP
Key Investors in Alimera Sciences
Domain Associates
DomainVC is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies. Its intended clients include biotech startups and investors looking to enter the biotech sector.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth. Their team consists of board members, entrepreneurs, scientists, and operators who engage deeply to foster innovation and collaboration. Polaris aims to support the development of modern solutions in various industries, exemplifying a commitment to nurturing relationships and enhancing the entrepreneurial journey.
Scale Venture Partners
Scale Venture Partners is an early-stage venture capital firm that invests in founders building category-defining businesses. They provide hands-on consulting and go-to-market advisory from experienced executives to support companies on their journey from founder-led growth to scalable operations. Their portfolio includes notable companies such as DocuSign, HubSpot, and Box, reflecting their commitment to backing innovative startups. The firm focuses on partnering with early-stage AI companies, helping them navigate the challenges of growth and market entry.
What's next for Alimera Sciences?
With substantial backing and a clear focus on retinal diseases, Alimera Sciences is poised for continued growth and development. The company's strategic financing initiatives suggest a trajectory aimed at expanding its commercial reach and advancing its product pipeline through rigorous research and development. Future endeavors will likely concentrate on bringing novel treatments to market, addressing critical needs in ophthalmology and solidifying its position in the pharmaceutical landscape.
See full Alimera Sciences company page
